Yablonka Uri 4

What Happened

• Uri Yablonka, EVP & Chief Business Officer and Director of BrainStorm Cell Therapeutics (BCLI), received an award of 150,000 restricted stock units (RSUs) on February 26, 2026. The award was granted at $0.00 (no cash paid at grant). This is a compensation grant rather than a market purchase or sale.

Key Details

• Transaction date: 2026-02-26; Grant type: Award/Acquisition (RSUs); Price reported: $0.00.
• Vesting: 50% of the RSUs vested on the grant date; the remaining 50% vests on the six‑month anniversary of the grant, contingent on continued employment (per footnote).
• Shares owned after transaction: Not specified in the provided filing.
• Filing date: 2026-05-29 (Form 4 filed ~3 months after the grant). This appears later than the typical 2-business-day Form 4 reporting requirement.
• Accession: 0001104659-26-068338.

Context

• RSUs are a form of equity compensation that convert into company shares upon vesting; no shares were purchased or sold in this transaction. Such grants are common for executive compensation and retention; they do not by themselves indicate a buy or sell signal.